Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 août 2023 16h30 HE
|
Gritstone bio
EMERYVILLE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio and Genevant Sciences Announce Option and License Agreement
15 août 2023 07h00 HE
|
Gritstone bio
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year,...
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
09 août 2023 16h05 HE
|
Gritstone bio
-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC);...
Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
07 août 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 juil. 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 juin 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications
08 juin 2023 07h00 HE
|
Gritstone bio
-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older adults...
Gritstone bio to Participate in Upcoming Investor Conferences
01 juin 2023 16h30 HE
|
Gritstone bio
EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 mai 2023 17h00 HE
|
Gritstone bio
EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced...
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
11 mai 2023 16h05 HE
|
Gritstone bio
-- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80...